Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T62431 | Target Info | |||
Target Name | Tyrosine-protein kinase SYK (SYK) | ||||
Synonyms |
p72-Syk; Spleen tyrosine kinase
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | SYK | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Fusion protein Bcr-Abl (Bcr-Abl) | Successful Target | ||||
UniProt ID | BCR_HUMAN-ABL1_HUMAN | |||||
Gene Name | BCR-ABL1 | |||||
Synonyms |
BCR-ABL fusion protein; BCR-ABL
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 1.1 nM | [1] | |||
Co-Target Name | Platelet-derived growth factor receptor alpha (PDGFRA) | Successful Target | ||||
UniProt ID | PGFRA_HUMAN | |||||
Gene Name | PDGFRA | |||||
Synonyms |
RHEPDGFRA; Platelet-derived growth factor receptor 2; Platelet-derived growth factor alpha receptor; PDGFR2; PDGFR-alpha; PDGFR-2; PDGF-R-alpha; CD140a antigen; CD140a; CD140 antigen-like family member A; Alpha-type platelet-derived growth factor receptor; Alpha platelet-derived growth factor receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 1.995 nM | Click to Show More | [2] | ||
2 | TAK-659 | Drug Info | IC50 = 45 nM | [3] | ||
Co-Target Name | Fms-like tyrosine kinase 3 (FLT-3) | Successful Target | ||||
UniProt ID | FLT3_HUMAN | |||||
Gene Name | FLT3 | |||||
Synonyms |
Stem cell tyrosine kinase 1; STK1; STK-1; Receptor-type tyrosine-protein kinase FLT3; Fetal liver kinase-2; FLT-3; FLK2; FLK-2; FL cytokine receptor; CD135
Click to Show/Hide
|
|||||
Representative Drug(s) | TAK-659 | Drug Info | IC50 = 4.6 nM | Click to Show More | [3] | |
2 | tamatinib | Drug Info | EC50 = 10 nM | [7] | ||
3 | Drug Info | IC50 = 131 nM | [16] | |||
4 | GS-9973 | Drug Info | EC50 = 327 nM | [7] | ||
Co-Target Name | Proto-oncogene c-Ret (RET) | Successful Target | ||||
UniProt ID | RET_HUMAN | |||||
Gene Name | RET | |||||
Synonyms |
RET51; RET receptor tyrosine kinase; RET mutant Y791F; RET mutant V804M; RET mutant V804L; RET mutant S891A; RET mutant M918T; RET mutant G691S; Proto-oncogene tyrosine-protein kinase receptor Ret; PTC; Cadherin family member 12; CDHR16; CDHF12; C-ret
Click to Show/Hide
|
|||||
Representative Drug(s) | tamatinib | Drug Info | IC50 = 5 nM | Click to Show More | [4] | |
2 | TAK-659 | Drug Info | IC50 = 8.4 nM | [3] | ||
3 | GS-9973 | Drug Info | EC50 ~ 1000 nM | [7] | ||
Co-Target Name | Janus kinase 2 (JAK-2) | Successful Target | ||||
UniProt ID | JAK2_HUMAN | |||||
Gene Name | JAK2 | |||||
Synonyms |
Tyrosine-protein kinase JAK2
Click to Show/Hide
|
|||||
Representative Drug(s) | tamatinib | Drug Info | IC50 = 6 nM | Click to Show More | [5] | |
2 | Cerdulatinib | Drug Info | IC50 = 6 nM | [6] | ||
3 | GS-9973 | Drug Info | EC50 = 453 nM | [7] | ||
Co-Target Name | Janus kinase 3 (JAK-3) | Successful Target | ||||
UniProt ID | JAK3_HUMAN | |||||
Gene Name | JAK3 | |||||
Synonyms |
Tyrosine-protein kinase JAK3; Leukocyte janus kinase; L-JAK
Click to Show/Hide
|
|||||
Representative Drug(s) | Cerdulatinib | Drug Info | IC50 = 8 nM | Click to Show More | [6] | |
2 | TAK-659 | Drug Info | IC50 = 114 nM | [3] | ||
Co-Target Name | Janus kinase 1 (JAK-1) | Successful Target | ||||
UniProt ID | JAK1_HUMAN | |||||
Gene Name | JAK1 | |||||
Synonyms |
Tyrosine-protein kinase JAK1; JAK1B; JAK1A
Click to Show/Hide
|
|||||
Representative Drug(s) | Cerdulatinib | Drug Info | IC50 = 12 nM | [6] | ||
Co-Target Name | Tyrosine-protein kinase ABL1 (ABL) | Successful Target | ||||
UniProt ID | ABL1_HUMAN | |||||
Gene Name | ABL1 | |||||
Synonyms |
p150; Proto-oncogene tyrosine-protein kinase ABL1; Proto-oncogene c-Abl; JTK7; C-ABL; Abl; Abelson tyrosine-protein kinase 1; Abelson murine leukemia viral oncogene homolog 1
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 13 nM | [8] | |||
Co-Target Name | Tyrosine-protein kinase Kit (KIT) | Successful Target | ||||
UniProt ID | KIT_HUMAN | |||||
Gene Name | KIT | |||||
Synonyms |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; p145 c-kit; Proto-oncogene tyrosine-protein kinase Kit; Proto-oncogene c-Kit; Piebald trait protein; PBT; Mast/stem cell growth factor receptor Kit; CD117 antigen; CD117; C-kit
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 16.4 nM | [9] | |||
Co-Target Name | Carbonic anhydrase II (CA-II) | Successful Target | ||||
UniProt ID | CAH2_HUMAN | |||||
Gene Name | CA2 | |||||
Synonyms |
Carbonic anhydrase C; Carbonic anhydrase 2; Carbonate dehydratase II; CAC
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 30.2 nM | [10] | |||
Co-Target Name | Carbonic anhydrase I (CA-I) | Successful Target | ||||
UniProt ID | CAH1_HUMAN | |||||
Gene Name | CA1 | |||||
Synonyms |
Carbonic anhydrase B; Carbonic anhydrase 1; Carbonate dehydratase I; CAB
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 31.9 nM | [10] | |||
Co-Target Name | Vascular endothelial growth factor receptor 2 (KDR) | Successful Target | ||||
UniProt ID | VGFR2_HUMAN | |||||
Gene Name | KDR | |||||
Synonyms |
VEGFR2; VEGFR-2; VEGF-2 receptor; Protein-tyrosine kinase receptor flk-1; Kinase insert domain receptor; Fetal liver kinase 1; FLK1; FLK-1; CD309
Click to Show/Hide
|
|||||
Representative Drug(s) | tamatinib | Drug Info | EC50 = 36 nM | Click to Show More | [7] | |
2 | TAK-659 | Drug Info | IC50 = 88 nM | [3] | ||
3 | GS-9973 | Drug Info | EC50 ~ 1000 nM | [7] | ||
Co-Target Name | Quinone reductase 2 (NQO2) | Successful Target | ||||
UniProt ID | NQO2_HUMAN | |||||
Gene Name | NQO2 | |||||
Synonyms |
Quinone oxidoreductase 2; Qui reductase 2; QR2; NRH:quinone oxidoreductase 2; NRH:qui oxidoreductase 2; NQO2; NAD(P)H qui oxidoreductase 2
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 39 nM | [11] | |||
Co-Target Name | Solute carrier family 47 member 1 (SLC47A1) | Successful Target | ||||
UniProt ID | S47A1_HUMAN | |||||
Gene Name | SLC47A1 | |||||
Synonyms |
hMATE-1; Multidrug and toxin extrusion protein 1; MATE1; MATE-1
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 40 nM | [12] | |||
Co-Target Name | Platelet-derived growth factor receptor (PDGFR) | Successful Target | ||||
UniProt ID | PGFRA_HUMAN; PGFRB_HUMAN | |||||
Gene Name | NO-GeName | |||||
Synonyms |
Platelet-derived growth factor receptor tyrosine kinase; PDGFR kinase; PDGF-R
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 50 nM | [13] | |||
Co-Target Name | Platelet-derived growth factor receptor beta (PDGFRB) | Successful Target | ||||
UniProt ID | PGFRB_HUMAN | |||||
Gene Name | PDGFRB | |||||
Synonyms |
Platelet-derived growth factor receptor 1; PDGFR1; PDGFR-beta; PDGFR-1; PDGFR; PDGF-R-beta; CD140b antigen; CD140b; CD140 antigen-like family member B; Beta-type platelet-derived growth factor receptor; Beta-PDGFR; Beta platelet-derived growth factor receptor
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 72 nM | [14] | |||
Co-Target Name | Protein kinase C alpha (PRKCA) | Successful Target | ||||
UniProt ID | KPCA_HUMAN | |||||
Gene Name | PRKCA | |||||
Synonyms |
Protein kinase C alpha type; PRKACA; PKCalpha; PKCA; PKC-alpha; PKC-A
Click to Show/Hide
|
|||||
Representative Drug(s) | PRT-062607 | Drug Info | IC50 = 90 nM | [15] | ||
Co-Target Name | LCK tyrosine protein kinase (LCK) | Successful Target | ||||
UniProt ID | LCK_HUMAN | |||||
Gene Name | LCK | |||||
Synonyms |
p56-LCK; Tyrosine-protein kinase Lck; T cell-specific protein-tyrosine kinase; Proto-oncogene tyrosine-protein kinase LCK; Proto-oncogene Lck; Protein YT16; Lymphocyte cell-specific protein-tyrosine kinase; Leukocyte C-terminal Src kinase; LSK; LCK p59-Fyn; LCK Protooncogene Syn
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 160 nM | [17] | |||
Co-Target Name | Carbonic anhydrase VI (CA-VI) | Successful Target | ||||
UniProt ID | CAH6_HUMAN | |||||
Gene Name | CA6 | |||||
Synonyms |
Secreted carbonic anhydrase; Salivary carbonic anhydrase; Carbonic anhydrase 6; Carbonate dehydratase VI
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 392 nM | [10] | |||
Co-Target Name | Carbonic anhydrase XIV (CA-XIV) | Successful Target | ||||
UniProt ID | CAH14_HUMAN | |||||
Gene Name | CA14 | |||||
Synonyms |
UNQ690/PRO1335; Carbonic anhydrase 14; Carbonate dehydratase XIV
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 468 nM | [10] | |||
Co-Target Name | Carbonic anhydrase XII (CA-XII) | Successful Target | ||||
UniProt ID | CAH12_HUMAN | |||||
Gene Name | CA12 | |||||
Synonyms |
Tumor antigen HOM-RCC-3.1.3; Carbonic anhydrase 12; Carbonate dehydratase XII
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 980 nM | [10] | |||
Co-Target Name | Voltage-gated potassium channel Kv11.1 (KCNH2) | Successful Target | ||||
UniProt ID | KCNH2_HUMAN | |||||
Gene Name | KCNH2 | |||||
Synonyms |
hERG1; hERG-1; Voltage-gated potassium channel subunit Kv11.1; Potassium voltage-gated channel subfamily H member 2; HERG K+ channel; HERG; H-ERG; Ether-a-go-go-related protein 1; Ether-a-go-go-related gene potassium channel 1; Ether-a-go-go related protein 1; Ether-a-go-go related gene potassium channel 1; Eag related protein 1; Eag homolog; ERG-1; ERG
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 ~ 1000 nM | [18] | |||
Co-Target Name | Stress-activated protein kinase JNK1 (JNK1) | Clinical trial Target | ||||
UniProt ID | MK08_HUMAN | |||||
Gene Name | MAPK8 | |||||
Synonyms |
Stress-activated protein kinase 1c; SAPK1c; PRKM8; Mitogen-activated protein kinase 8; MAPK 8; MAP kinase 8; JNK-46; C-Jun N-terminal kinase 1
Click to Show/Hide
|
|||||
Representative Drug(s) | tamatinib | Drug Info | EC50 = 10 nM | [4] | ||
Co-Target Name | Checkpoint kinase-1 (CHK1) | Clinical trial Target | ||||
UniProt ID | CHK1_HUMAN | |||||
Gene Name | CHEK1 | |||||
Synonyms |
Serine/threonine-protein kinase Chk1; Chk1; Cell cycle checkpoint kinase; CHK1 checkpoint homolog
Click to Show/Hide
|
|||||
Representative Drug(s) | TAK-659 | Drug Info | IC50 = 50 nM | [3] | ||
Co-Target Name | Carbonic anhydrase IX (CA-IX) | Clinical trial Target | ||||
UniProt ID | CAH9_HUMAN | |||||
Gene Name | CA9 | |||||
Synonyms |
Renal cell carcinoma-associated antigen G250; RCC-associated antigen G250; PMW1; P54/58N; Membrane antigen MN; MN; G250 antigen (MN/CA IX/G250); G250; Carbonic anhydrase 9; Carbonate dehydratase IX; CAIX
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 75.7 nM | [10] | |||
Co-Target Name | PAK-4 protein kinase (PAK4) | Clinical trial Target | ||||
UniProt ID | PAK4_HUMAN | |||||
Gene Name | PAK4 | |||||
Synonyms |
p21-activated kinase 4; Serine/threonine-protein kinase PAK 4; PAK-4; KIAA1142
Click to Show/Hide
|
|||||
Representative Drug(s) | TAK-659 | Drug Info | IC50 = 76 nM | [3] | ||
Co-Target Name | Tyrosine-protein kinase Lyn (JTK8) | Clinical trial Target | ||||
UniProt ID | LYN_HUMAN | |||||
Gene Name | LYN | |||||
Synonyms |
p56Lyn; p53Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; Lck/Yes-related novel protein tyrosine kinase
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 220 nM | Click to Show More | [19] | ||
2 | PRT-062607 | Drug Info | IC50 = 238 nM | [5] | ||
3 | tamatinib | Drug Info | IC50 = 732 nM | [5] | ||
Co-Target Name | Macrophage colony-stimulating factor 1 receptor (CSF1R) | Clinical trial Target | ||||
UniProt ID | CSF1R_HUMAN | |||||
Gene Name | CSF1R | |||||
Synonyms |
Proto-oncogene c-Fms; M-CSF-R; FMS; CSF-1R; CSF-1-R; CSF-1 receptor; CD115
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 291 nM | [14] | |||
Co-Target Name | Stress-activated protein kinase JNK2 (JNK2) | Patented-recorded Target | ||||
UniProt ID | MK09_HUMAN | |||||
Gene Name | MAPK9 | |||||
Synonyms |
Stress-activated protein kinase 1a; SAPK1a; PRKM9; Mitogen-activated protein kinase 9; Mitogen-activated protein kinase 8-interacting protein 2; MAPK 9; MAP kinase 9; Jun-N-terminal kinase 2; JNK-interacting protein 2; JNK-55; JNK MAP kinase scaffold protein 2; JIP-2; Islet-brain-2; IB-2; C-jun-amino-terminal kinase interacting protein 2; C-Jun N-terminal kinase 2
Click to Show/Hide
|
|||||
Representative Drug(s) | tamatinib | Drug Info | EC50 = 10 nM | [4] | ||
Co-Target Name | Tyrosine-protein kinase ZAP-70 (ZAP-70) | Patented-recorded Target | ||||
UniProt ID | ZAP70_HUMAN | |||||
Gene Name | ZAP70 | |||||
Synonyms |
Syk-related tyrosine kinase; SRK; 70 kDa zeta-chain associated protein
Click to Show/Hide
|
|||||
Representative Drug(s) | tamatinib | Drug Info | IC50 = 42 nM | Click to Show More | [5] | |
2 | PRT-062607 | Drug Info | IC50 = 60 nM | [5] | ||
3 | TAK-659 | Drug Info | IC50 = 75 nM | [3] | ||
Co-Target Name | Epithelial discoidin domain receptor 1 (DDR1) | Patented-recorded Target | ||||
UniProt ID | DDR1_HUMAN | |||||
Gene Name | DDR1 | |||||
Synonyms |
Tyrosine-protein kinase CAK; Tyrosine kinase DDR; TRKE; TRK E; RTK6; Protein-tyrosine kinase RTK-6; Protein-tyrosine kinase 3A; PTK3A; NTRK4; NEP; Mammary carcinoma kinase 10; MCK-10; HGK2; Epithelial discoidin domain-containing receptor 1; EDDR1; Discoidin receptor tyrosine kinase; Cell adhesion kinase; CD167a; CD167 antigen-like family member A
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 43 nM | [14] | |||
Co-Target Name | Carbonic anhydrase VII (CA-VII) | Patented-recorded Target | ||||
UniProt ID | CAH7_HUMAN | |||||
Gene Name | CA7 | |||||
Synonyms |
Carbonic anhydrase 7; Carbonate dehydratase VII
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 109 nM | [10] | |||
Co-Target Name | Discoidin domain-containing receptor 2 (DDR2) | Patented-recorded Target | ||||
UniProt ID | DDR2_HUMAN | |||||
Gene Name | DDR2 | |||||
Synonyms |
Tyrosine-protein kinase TYRO10; Receptor protein-tyrosine kinase TKT; Neurotrophic tyrosine kinase, receptor-related 3; Discoidin domain-containing receptor tyrosine kinase 2; Discoidin domain receptor 2; DDR2; CD167 antigen-like family member B
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 141 nM | [14] | |||
Co-Target Name | Ephrin type-A receptor 1 (EPHA1) | Literature-reported Target | ||||
UniProt ID | EPHA1_HUMAN | |||||
Gene Name | EPHA1 | |||||
Synonyms |
hEpha1; Tyrosine-protein kinase receptor EPH; Erythropoietin-producing hepatoma receptor; EPHT1; EPHT; EPH tyrosine kinase 1; EPH tyrosine kinase; EPH
Click to Show/Hide
|
|||||
Representative Drug(s) | TAK-659 | Drug Info | IC50 = 31 nM | [3] | ||
Co-Target Name | Proto-oncogene c-Fer (FER) | Literature-reported Target | ||||
UniProt ID | FER_HUMAN | |||||
Gene Name | FER | |||||
Synonyms |
p94-Fer; Tyrosine-protein kinase Fer; Tyrosine kinase 3; TYK3; Fujinami poultry sarcoma/Feline sarcoma-related protein Fer; Feline encephalitis virus-related kinase FER
Click to Show/Hide
|
|||||
Representative Drug(s) | TAK-659 | Drug Info | IC50 = 51 nM | [3] | ||
Co-Target Name | Phosphorylase kinase testis gamma 2 (PHKG2) | Literature-reported Target | ||||
UniProt ID | PHKG2_HUMAN | |||||
Gene Name | PHKG2 | |||||
Synonyms |
Phosphorylase kinase subunit gamma-2; Phosphorylase b kinase gamma catalytic chain, liver/testis isoform; PSK-C3; PHK-gamma-T; PHK-gamma-LT
Click to Show/Hide
|
|||||
Representative Drug(s) | TAK-659 | Drug Info | IC50 = 226 nM | [3] | ||
Co-Target Name | Tyrosine-protein kinase ABL2 (ABL2) | Literature-reported Target | ||||
UniProt ID | ABL2_HUMAN | |||||
Gene Name | ABL2 | |||||
Synonyms |
Tyrosine-protein kinase ARG; Abelson-related gene protein; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; ARG; ABLL
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 272 nM | [11] | |||
Co-Target Name | Multidrug and toxin extrusion protein 2 (MATE2) | Literature-reported Target | ||||
UniProt ID | S47A2_HUMAN | |||||
Gene Name | SLC47A2 | |||||
Synonyms |
hMATE-2; Solute carrier family 47 member 2; MATE2; MATE-2; Kidney-specific H(+)/organic cation antiporter
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | IC50 = 350 nM | [12] | |||
Co-Target Name | Mitogen-activated protein kinase 1 (MAPK1) | Co-Target | ||||
UniProt ID | MK01_HUMAN | |||||
Gene Name | MAPK1 | |||||
Synonyms |
MAP kinase 1; MAPK 1; ERT1; Extracellular signal-regulated kinase 2; ERK-2; MAP kinase isoform p42; p42-MAPK; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2
Click to Show/Hide
|
|||||
Representative Drug(s) | tamatinib | Drug Info | EC50 = 10 nM | [4] | ||
Co-Target Name | Mitogen-activated protein kinase 3 (MAPK3) | Co-Target | ||||
UniProt ID | MK03_HUMAN | |||||
Gene Name | MAPK3 | |||||
Synonyms |
MAP kinase 3; MAPK 3; ERT2; Extracellular signal-regulated kinase 1; ERK-1; Insulin-stimulated MAP2 kinase; MAP kinase isoform p44; p44-MAPK; Microtubule-associated protein 2 kinase; p44-ERK1
Click to Show/Hide
|
|||||
Representative Drug(s) | tamatinib | Drug Info | EC50 = 10 nM | [4] | ||
Co-Target Name | Carbonic anhydrase III (CA3) | Co-Target | ||||
UniProt ID | CAH3_HUMAN | |||||
Gene Name | CA3 | |||||
Synonyms |
Carbonic anhydrase 3; Carbonate dehydratase III; CA-III
Click to Show/Hide
|
|||||
Representative Drug(s) | Drug Info | Ki = 528 nM | [10] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Selectively nonselective kinase inhibition: striking the right balance. J Med Chem. 2010 Feb 25;53(4):1413-37. | ||||
REF 2 | Selectivity data: assessment, predictions, concordance, and implications. J Med Chem. 2013 Sep 12;56(17):6991-7002. | ||||
REF 3 | Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-50. | ||||
REF 4 | Discovery and development of spleen tyrosine kinase (SYK) inhibitors. J Med Chem. 2012 Apr 26;55(8):3614-43. | ||||
REF 5 | Syk inhibitors with high potency in presence of blood. Bioorg Med Chem Lett. 2014 May 15;24(10):2278-82. | ||||
REF 6 | Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. J Med Chem. 2018 Nov 21;61(22):9811-40. | ||||
REF 7 | Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014 May 8;57(9):3856-73. | ||||
REF 8 | Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines. Eur J Med Chem. 2008 Dec;43(12):2665-76. | ||||
REF 9 | Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. J Med Chem. 2017 Nov 9;60(21):8801-15. | ||||
REF 10 | The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4102-6. | ||||
REF 11 | Non-kinase targets of protein kinase inhibitors. Nat Rev Drug Discov. 2017 Jun;16(6):424-40. | ||||
REF 12 | Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013 Feb 14;56(3):781-795. | ||||
REF 13 | Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. | ||||
REF 14 | Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem. 2010 Oct 1;18(19):6977-86. | ||||
REF 15 | Discovery and profiling of a selective and efficacious Syk inhibitor. J Med Chem. 2015 Feb 26;58(4):1950-63. | ||||
REF 16 | Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. J Med Chem. 2019 Dec 26;62(24):11135-11150. | ||||
REF 17 | 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13;52(15):4743-56. | ||||
REF 18 | Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors. J Med Chem. 2013 Feb 28;56(4):1677-92. | ||||
REF 19 | Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg Med Chem Lett. 2007 May 15;17(10):2712-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.